Mosley Wealth Management Raises Holdings in Amgen Inc. (NASDAQ:AMGN)

Mosley Wealth Management lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 6.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,151 shares of the medical research company’s stock after purchasing an additional 73 shares during the quarter. Mosley Wealth Management’s holdings in Amgen were worth $360,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Aveo Capital Partners LLC raised its stake in shares of Amgen by 19.9% in the fourth quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock worth $786,000 after purchasing an additional 453 shares during the last quarter. Gryphon Financial Partners LLC boosted its holdings in shares of Amgen by 295.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock valued at $1,021,000 after acquiring an additional 2,752 shares during the last quarter. Principal Securities Inc. acquired a new stake in shares of Amgen in the fourth quarter worth $2,866,000. Calton & Associates Inc. purchased a new position in shares of Amgen during the fourth quarter worth $251,000. Finally, Thompson Siegel & Walmsley LLC lifted its position in Amgen by 121.4% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 25,893 shares of the medical research company’s stock valued at $7,458,000 after purchasing an additional 14,200 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AMGN shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Oppenheimer reiterated an “outperform” rating and issued a $380.00 target price on shares of Amgen in a research note on Wednesday, August 7th. Jefferies Financial Group restated a “buy” rating and set a $380.00 price target (up previously from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Bank of America upped their price objective on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada raised their target price on Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average price target of $327.28.

Amgen Trading Down 1.2 %

AMGN traded down $3.80 during mid-day trading on Friday, hitting $320.56. 2,242,451 shares of the stock were exchanged, compared to its average volume of 2,541,291. The firm’s fifty day moving average is $326.26 and its two-hundred day moving average is $302.12. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a market cap of $171.96 billion, a PE ratio of 45.79, a PEG ratio of 2.96 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same period in the prior year, the company posted $5.00 EPS. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.81%. Amgen’s dividend payout ratio (DPR) is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.